• LAST PRICE
    141.5000
  • TODAY'S CHANGE (%)
    Trending Down-0.7900 (-0.5552%)
  • Bid / Lots
    141.2200/ 4
  • Ask / Lots
    141.5100/ 1
  • Open / Previous Close
    142.3000 / 142.2900
  • Day Range
    Low 139.7700
    High 143.0500
  • 52 Week Range
    Low 89.0400
    High 148.3699
  • Volume
    216,662
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 142.29
TimeVolumeNBIX
09:32 ET8831142.65
09:34 ET1477142.91
09:36 ET792142.55
09:38 ET1609141.63
09:39 ET100141.76
09:41 ET1032142.15
09:43 ET446142.26
09:45 ET12905142.135
09:48 ET1212141.65
09:50 ET880141.2
09:52 ET100141.22
09:54 ET600141.15
09:57 ET100141.4989
09:59 ET115141.25
10:01 ET954141.25
10:03 ET1500141.12
10:08 ET100141.195
10:10 ET1738140.69
10:12 ET400140.89
10:15 ET600140.515
10:17 ET700140.35
10:19 ET400140.265
10:21 ET250140.5744
10:24 ET100140.445
10:26 ET700140.23
10:28 ET545140
10:30 ET1400140.05
10:32 ET2208139.94
10:33 ET1834140.13
10:35 ET800140.53
10:37 ET300140.5
10:39 ET1241140.25
10:42 ET100140.16
10:44 ET200140.21
10:48 ET3495140.03
10:50 ET695140.02
10:51 ET1569140.21
10:53 ET614140.14
10:55 ET725140.12
10:57 ET1249140.305
11:00 ET300140.4
11:02 ET1725140.315
11:04 ET347140.2035
11:06 ET350140.29
11:08 ET1050140.1101
11:09 ET300140.29
11:13 ET1366140
11:15 ET500140.0275
11:18 ET400140.06
11:20 ET400140.03
11:22 ET5283140.03
11:24 ET1005140.06
11:26 ET601140.02
11:27 ET520139.98
11:29 ET6497140
11:31 ET858140.01
11:33 ET200140.07
11:36 ET700139.94
11:38 ET700139.93
11:40 ET300140.025
11:42 ET100139.95
11:44 ET400140.09
11:45 ET800139.96
11:49 ET515140.005
11:51 ET200139.955
11:54 ET864140.05
11:56 ET750140.05
11:58 ET240140.0492
12:00 ET2144139.955
12:02 ET250139.885
12:03 ET1000139.78
12:05 ET1700140.11
12:07 ET669140.14
12:09 ET100140.115
12:12 ET1150140.115
12:16 ET1569140.1501
12:18 ET150140.2
12:21 ET200140.39
12:23 ET100140.375
12:25 ET200140.33
12:27 ET200140.35
12:30 ET300140.29
12:32 ET200140.32
12:34 ET100140.26
12:36 ET200140.36
12:38 ET1252140.425
12:39 ET564140.62
12:41 ET400140.81
12:43 ET300140.85
12:45 ET100140.875
12:48 ET700140.82
12:50 ET1900140.69
12:52 ET300140.86
12:54 ET700141.23
12:56 ET300141.31
12:57 ET1073141.275
01:01 ET400141.14
01:03 ET200141.19
01:06 ET100141.215
01:08 ET300141.255
01:10 ET300141.34
01:12 ET154141.3
01:14 ET925141.265
01:15 ET400141.265
01:17 ET222141.14
01:19 ET472141.0127
01:21 ET300141.105
01:24 ET635140.995
01:26 ET424140.995
01:28 ET1453141.16
01:32 ET100141.12
01:33 ET160141.14
01:37 ET342141.29
01:39 ET100141.35
01:44 ET200141.42
01:46 ET100141.45
01:48 ET749141.21
01:50 ET470141.14
01:53 ET1600141.5
01:55 ET100141.5
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNBIX
Neurocrine Biosciences Inc
14.3B
38.9x
+62.04%
United StatesMEDP
Medpace Holdings Inc
12.2B
40.7x
+35.10%
United StatesBMRN
Biomarin Pharmaceutical Inc
14.7B
72.3x
---
United StatesQGEN
Qiagen NV
10.1B
29.8x
+12.66%
United StatesUTHR
United Therapeutics Corp
12.2B
12.9x
+8.22%
United StatesALNY
Alnylam Pharmaceuticals Inc
18.9B
-55.1x
---
As of 2024-05-20

Company Information

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

Contact Information

Headquarters
6027 EDGEWOOD BEND COURTSAN DIEGO, CA, United States 92130
Phone
858-617-7600
Fax
858-617-7602

Executives

Non-Executive Independent Chairman of the Board
William Rastetter
Chief Executive Officer, Director
Kevin Gorman
Chief Financial Officer
Matthew Abernethy
Chief Human Resource Officer
Julie Cooke
Chief Scientific Officer
Jude Onyia

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$14.3B
Revenue (TTM)
$2.0B
Shares Outstanding
100.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.37
EPS
$3.64
Book Value
$22.61
P/E Ratio
38.9x
Price/Sales (TTM)
7.2
Price/Cash Flow (TTM)
36.5x
Operating Margin
23.43%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.